Related Experiment Video
Updated: Jul 1, 2025

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
Published on: April 27, 2018
In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis
Juan M Arriaga1,2, Kacey Ronaldson-Bouchard3, Florencia Picech4
1Department of Molecular Pharmacology and Therapeutics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, 10032, USA. juan.arriaga@mssm.edu.
Abstract:
Most cancer deaths are due to metastatic dissemination to distant organs. Bone is the most frequently affected organ in metastatic prostate cancer and a major cause of prostate cancer deaths. Yet, our partial understanding of the molecular factors that drive bone metastasis has been a limiting factor for developing preventative and therapeutic strategies to improve patient survival and well-being. Although recent studies have uncovered molecular alterations that occur in prostate cancer metastasis, their functional relevance for bone metastasis is not well understood. Using genome-wide CRISPR activation and inhibition screens we have identified multiple drivers and suppressors of prostate cancer metastasis. Through functional validation, including an innovative organ-on-a-chip invasion platform for studying bone tropism, our study identifies the transcriptional modulator CITED2 as a novel driver of prostate cancer bone metastasis and uncovers multiple new potential molecular targets for bone metastatic disease.
Insights
Researchers identified CITED2 as a key driver of prostate cancer bone metastasis. This discovery offers new molecular targets for preventing and treating this deadly cancer spread.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Metastasis Research
Background:
- Metastatic prostate cancer frequently spreads to bone, leading to significant mortality.
- Limited understanding of molecular drivers hinders effective treatment strategies for bone metastasis.
- Previous studies identified molecular alterations in prostate cancer metastasis, but their role in bone tropism remains unclear.
Purpose of the Study:
- To identify novel molecular drivers and suppressors of prostate cancer bone metastasis.
- To elucidate the functional relevance of molecular alterations in prostate cancer bone tropism.
- To uncover new therapeutic targets for managing bone metastatic prostate cancer.
Main Methods:
- Genome-wide CRISPR activation and inhibition screens were employed to identify key genes.
- Functional validation studies were conducted to confirm identified targets.
- An innovative organ-on-a-chip invasion platform was utilized to study bone tropism.
Main Results:
- Multiple genetic drivers and suppressors of prostate cancer metastasis were identified through CRISPR screens.
- The transcriptional modulator CITED2 was confirmed as a novel driver of prostate cancer bone metastasis.
- The study uncovered several new potential molecular targets for treating bone metastatic disease.
Conclusions:
- CITED2 plays a critical role in promoting prostate cancer metastasis to bone.
- This research provides novel insights into the molecular mechanisms of bone metastasis.
- The identified targets offer promising avenues for developing future therapeutic interventions for prostate cancer bone metastasis.
More Related Videos
Related Concept Videos
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

